Below follows a selection of references and original publications. Further and more recent research results are submitted for publication but have not yet reached acceptance status.
Mertens, B., et al.
Direct angiotensin II type 2 receptor stimulation decreases dopamine synthesis in the rat striatum, Neuropharmacology (2010), doi:10.1016/j.neuropharm.2010.01.009
Bosnyak S et al
Stimulation of angiotensin AT2 receptors by the non-peptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats. British Journal of Pharmacology (2010) doi:10.1111/j.1476-5381.2009.00575.x
Rompe F et al
Direct Angiotensin II Type 2 Receptor Stimulation Acts Anti-Inflammatory Through Epoxyeicosatrienoic Acid and Inhibition of Nuclear Factor kB. Journal of Hypertension. 2010;55:924-931.
Sironi L et al
Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: focus on renal damage. Journal of Hypertension 27: 0. 2009
Unger T and Dahlöf B
Compound 21, the first orally active, selective agonist of the angiotensin II type 2 (AT2) receptor: implications for AT2 receptor research and therapeutic potential. Journal of Renin-Angiotensin-Aldosterone System In press 2009 (oct)
Steckelings U et al
The past, present and future of angiotensin II type 2 receptor stimulationJournal of Renin-Angiotensin-Aldosterone System. In press. 2009 (oct)
Kaschina E et al
AT2-receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction. Circulation. 2008
Batenburg WW, Garrelds IM, Bernasconi CC, Juillerat-Jeanneret L, van Kats JP, Saxena PR, Danser AH. Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries. Circulation. 2004 May 18;109(19) :2296-3
Benndorf, Böger, Ergun, Steenpass. Wieland: Angiotensin II type 2 receptor inhibits vascular endothelial growth factor-induced migration and in vitro tube formation in human endothelial cells. Circ Res 93: 2003
Carey RM, Jin XH, Siragy HM. Role of the angiotensin AT 2 receptor in blood pressure regulation and therapeutic implications. Am J Hypertens. 14(6):98S-102S, 2001 .
Davy KP, Hall JE. Obesity and hypertension: two epidemics or one? Am J Physiol Regul Integr Comp Physiol 2004 May ;286(5):R803-13.
De Paepe B, Verstraeten VLRM, De Potter CR, Bullock GR . Increased angiotensin II type-2 receptor density in hyperplasia, DCIS and invasive carcinoma of the breast is paralleled with increased iNOS expression. Histochem Cell Biol. 117:13-19, 2002.
Fournier A, Messerli FH, Achard JM, Fernandez L. Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials. J Am Coll Cardiol. 2004 Apr 21 ;43(8):1343-7
Gallinat S, Busche S, Raizada MK, Sumners C . The angiotensin II type 2 receptor: an enigma with multiple variations. Am J Physiol Endocrinol Metab. 278(3):E357-74, 2000 .
de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger TH . International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 52(3):415-72, 2000 .
Iwai M, Liu HW, Chen R, Ide A, Okamoto S, Hata R, Sakanaka M, Shiuchi T, Horiuchi M . Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation. 2004 Aug 17 ;110(7):843-8.
Johansson B, Holm M, Ewert S, Casselbrant A, Pettersson A, Fandriks L .
Angiotensin II type 2 receptor-mediated duodenal mucosal alkaline secretion in the rat. Am J Physiol; Gastrointest Liver Physiol 280(6):G1254-60, 2001 .
Kaschua E, Unger T. Angiotensin AT1/AT 2 Receptors: Regulation, Signalling and Function. Blood Pressure;12:70-88 2003
Unger T . The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol. 89(Suppl):3A-9A, 2002 .
Wan Y, Wallinder C, Johansson B, Holm M, Mahalingam AK, Wu X, Botros M, Karlen A, Pettersson A, Nyberg F, Fandriks L, Hallberg A, Alterman M. First reported nonpeptide AT1 receptor agonist (L-162,313) acts as an AT 2 receptor agonist in vivo. J Med Chem. 2004 Mar 11 ;47(6):1536-46.
Wan Y, Wallinder C, Plouffe B, Beaudry H, Mahalingham A K, Xiongyu W, Johansson B, Holm M, Botros M, Karlén A, Pettersson A, Nyberg F, Fändriks L, Gallo-Payet N, Hallberg A, Alterman M . Design, Synthesis and Biological Evaluation of the First Selective Nonpeptide AT 2 Receptor Agonist. J Med Chem in press
Widdop RE, Jones ES, Hnnan RE, Gaspari TA . Angiotensin AT 2 receptors: cardiovascular hope or hype? Br J Pharmacol. 2003 Nov ;140(5):809-24.
Volpe, Musumeci, De Paolis, Savona, Morganti : Angiotensin II AT 2 receptor subtype:
An uprising frontier in cardiovascular disease? Journal of Hypertension 21:1429-1443 2003